Drug shrinks tumors before surgery in skin cancer trial
NCT ID NCT04154943
Summary
This study tested whether giving an immunotherapy drug called cemiplimab to patients before surgery could help shrink their advanced skin cancer tumors. The goal was to see if this approach led to better surgical outcomes and longer survival. The trial involved 79 patients with a type of skin cancer called cutaneous squamous cell carcinoma that had not spread to other organs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Palo Alto, California, 94304, United States
-
Regeneron Study Site
Washington D.C., District of Columbia, 20037, United States
-
Regeneron Study Site
Miami, Florida, 33176, United States
-
Regeneron Study Site
Tampa, Florida, 33612, United States
-
Regeneron Study Site
Baltimore, Maryland, 21231, United States
-
Regeneron Study Site
Boston, Massachusetts, 02114, United States
-
Regeneron Study Site
Boston, Massachusetts, 02215, United States
-
Regeneron Study Site
Ann Arbor, Michigan, 48109, United States
-
Regeneron Study Site
Omaha, Nebraska, 68114, United States
-
Regeneron Study Site
New York, New York, 10065, United States
-
Regeneron Study Site
Charlotte, North Carolina, 28204, United States
-
Regeneron Study Site
Durham, North Carolina, 27710, United States
-
Regeneron Study Site
Cleveland, Ohio, 44195, United States
-
Regeneron Study Site
Dallas, Texas, 75390, United States
-
Regeneron Study Site
Houston, Texas, 77030, United States
-
Regeneron Study Site
St Leonards, New South Wales, 2065, Australia
-
Regeneron Study Site
Herston, Queensland, 4029, Australia
-
Regeneron Study Site
Melbourne, Victoria, 3000, Australia
-
Regeneron Study Site
Dresden, 01307, Germany
-
Regeneron Study Site
Essen, 45147, Germany
-
Regeneron Study Site
Kiel, 24105, Germany
-
Regeneron Study Site
Tübingen, 72076, Germany
Conditions
Explore the condition pages connected to this study.